✦ LIBER ✦

A Phase II Study of the MDR Inhibitor Biricodar (INCEL, VX-710) and Paclitaxel in Women with Advanced Ovarian Cancer Refractory to Paclitaxel Therapy

✍ Scribed by Michael V. Seiden; Kenneth D. Swenerton; Ursula Matulonis; Susan Campos; Peter Rose; Gerald Batist; Ene Ette; Varun Garg; Arlan Fuller; Matthew W. Harding; Danielle Charpentier

Book ID: 112251915
Publisher: Elsevier Science
Year: 2002
Tongue: English
Weight: 88 KB
Volume: 86
Category: Article
ISSN: 0090-8258
DOI: 10.1006/gyno.2002.6762

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

A Phase II study of IncelTM (biricodar,

A Phase II study of IncelTM (biricodar, VX-710) in combination with paclitaxel in women with advanced breast cancer refractory to paclitaxel

✍ Toppmeyer, D.; Seidman, A.; Overmoyer, B.; Pollak, M.; Verma, S.; Russell, C.; T 📂 Article 📅 1999 🏛 Elsevier Science 🌐 English ⚖ 170 KB

Safety and efficacy of the MDR inhibitor

Safety and efficacy of the MDR inhibitor Incel (biricodar, VX-710) in combination with mitoxantrone and prednisone in hormone-refractory prostate cancer

✍ Randall P. Rago; Albert Einstein; Richard Lush; Tomasz M. Beer; Yoo-Joung Ko; W. 📂 Article 📅 2003 🏛 Springer 🌐 English ⚖ 238 KB

A Phase II study of the safety, pharmaco

A Phase II study of the safety, pharmacokinetics and efficacy of IncelTM (biricodar, VX-710) in combination with mitoxantrone (M) and prednisone (P) in advanced hormone refractory prostate cancer (HRPC)

✍ Einstein, A.; Lush, R.; Rago, R.; Bubley, G.; Henner, W.D.; Chatta, G.; Shepard, 📂 Article 📅 1999 🏛 Elsevier Science 🌐 English ⚖ 149 KB

714 - Phase II trial of paclitaxel (P) a

714 - Phase II trial of paclitaxel (P) and cisplatin (COOP) in patients with advanced breast cancer refractory to anthracycline (A) therapy

✍ F. Riccardi; G. Rosati; M. Biglietto; G. Cartenì; P. De Rosa; A. Tucci; G. Pacil 📂 Article 📅 1997 🏛 Elsevier Science 🌐 English ⚖ 218 KB

Gemcitabine and oxaliplatin followed by

Gemcitabine and oxaliplatin followed by paclitaxel and carboplatin as first line therapy for patients with suboptimally debulked, advanced epithelial ovarian cancer. A phase II trial of sequential doublets. The GO-First Study

✍ C.B. Steer; K. Chrystal; K.A. Cheong; E. Galani; G.M. Marx; A.H. Strickland; D. 📂 Article 📅 2006 🏛 Elsevier Science 🌐 English ⚖ 146 KB

344 POSTER A phase Ib dose escalation st

344 POSTER A phase Ib dose escalation study to evaluate safety and tolerability of the combination of the aminopeptidase inhibitor CHR-2797 and paclitaxel in patients with advanced or treatment refractory tumors

✍ C. van Herpen; F. Eskens; M. de Jonge; I. Desar; L. Hooftman; E. Bone; A. Timmer 📂 Article 📅 2008 🏛 Elsevier Science 🌐 English ⚖ 59 KB